420 related articles for article (PubMed ID: 17998256)
1. Serum GFAP is a diagnostic marker for glioblastoma multiforme.
Jung CS; Foerch C; Schänzer A; Heck A; Plate KH; Seifert V; Steinmetz H; Raabe A; Sitzer M
Brain; 2007 Dec; 130(Pt 12):3336-41. PubMed ID: 17998256
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas.
Brommeland T; Rosengren L; Fridlund S; Hennig R; Isaksen V
Acta Neurol Scand; 2007 Dec; 116(6):380-4. PubMed ID: 17986096
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma.
Tichy J; Spechtmeyer S; Mittelbronn M; Hattingen E; Rieger J; Senft C; Foerch C
J Neurooncol; 2016 Jan; 126(2):361-9. PubMed ID: 26518540
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of glial fibrillary acidic protein (GFAP) do not indicate tumor recurrence in patients with glioblastoma.
Vietheer JM; Rieger J; Wagner M; Senft C; Tichy J; Foerch C
J Neurooncol; 2017 Oct; 135(1):193-199. PubMed ID: 28717884
[TBL] [Abstract][Full Text] [Related]
5. Correlation of glial fibrillary acidic protein (GFAP) with grading of the neuroglial tumours.
Reyaz N; Tayyab M; Khan SA; Siddique T
J Coll Physicians Surg Pak; 2005 Aug; 15(8):472-5. PubMed ID: 16202357
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological study on malignant glioma--with special reference to GFAP].
Tajika T; Kubo O; Tajika Y; Toyama T; Himuro H; Inoue N; Sakairi M; Kitamura K
No Shinkei Geka; 1986 Jun; 14(7):831-5. PubMed ID: 3020463
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
[TBL] [Abstract][Full Text] [Related]
8. Rapid immunoassay for the determination of glial fibrillary acidic protein (GFAP) in serum.
Vissers JL; Mersch ME; Rosmalen CF; van Heumen MJ; van Geel WJ; Lamers KJ; Rosmalen FM; Swinkels LM; Thomsen J; Herrmann M
Clin Chim Acta; 2006 Apr; 366(1-2):336-40. PubMed ID: 16405937
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma multiforme: clinical findings, magnetic resonance imaging, and pathology in five dogs.
Lipsitz D; Higgins RJ; Kortz GD; Dickinson PJ; Bollen AW; Naydan DK; LeCouteur RA
Vet Pathol; 2003 Nov; 40(6):659-69. PubMed ID: 14608019
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
[TBL] [Abstract][Full Text] [Related]
11. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome.
Nylén K; Ost M; Csajbok LZ; Nilsson I; Blennow K; Nellgård B; Rosengren L
J Neurol Sci; 2006 Jan; 240(1-2):85-91. PubMed ID: 16266720
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke.
Dvorak F; Haberer I; Sitzer M; Foerch C
Cerebrovasc Dis; 2009; 27(1):37-41. PubMed ID: 19018136
[TBL] [Abstract][Full Text] [Related]
13. Gliosarcoma: a histologic and immunohistochemical reaffirmation.
Meis JM; Ho KL; Nelson JS
Mod Pathol; 1990 Jan; 3(1):19-24. PubMed ID: 2155418
[TBL] [Abstract][Full Text] [Related]
14. Enhanced glial fibrillary acidic protein-delta expression in human astrocytic tumor.
Choi KC; Kwak SE; Kim JE; Sheen SH; Kang TC
Neurosci Lett; 2009 Oct; 463(3):182-7. PubMed ID: 19647039
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical study of S-phase cells in human gliomas].
Ibayashi N; Hirakawa K; Suzuki K; Nakamura K; Houri T
No To Shinkei; 1988 Aug; 40(8):763-9. PubMed ID: 2460117
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma multiforme in skin: a report of 2 cases and review of the literature.
Mentrikoski M; Johnson MD; Korones DN; Scott GA
Am J Dermatopathol; 2008 Aug; 30(4):381-4. PubMed ID: 18645311
[TBL] [Abstract][Full Text] [Related]
17. Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study.
Tena-Suck ML; Moreno-Jiménez S; Alonso M; Aguirre-Crux L; Sánchez A
Ann Diagn Pathol; 2008 Oct; 12(5):313-21. PubMed ID: 18774492
[TBL] [Abstract][Full Text] [Related]
18. Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis.
Reddy SP; Britto R; Vinnakota K; Aparna H; Sreepathi HK; Thota B; Kumari A; Shilpa BM; Vrinda M; Umesh S; Samuel C; Shetty M; Tandon A; Pandey P; Hegde S; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Kondaiah P; Somasundaram K; Rao MR
Clin Cancer Res; 2008 May; 14(10):2978-87. PubMed ID: 18483363
[TBL] [Abstract][Full Text] [Related]
19. Astrocytoma grade IV (glioblastoma multiforme) displays 3 subtypes with unique expression profiles of intermediate filament proteins.
Skalli O; Wilhelmsson U; Orndahl C; Fekete B; Malmgren K; Rydenhag B; Pekny M
Hum Pathol; 2013 Oct; 44(10):2081-8. PubMed ID: 23791210
[TBL] [Abstract][Full Text] [Related]
20. Microscopic thrombi in glioblastoma multiforme do not predict the development of deep venous thrombosis.
Prayson NF; Angelov L; Prayson RA
Ann Diagn Pathol; 2009 Oct; 13(5):291-6. PubMed ID: 19751904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
